PARP inhibitors: Treating mCRPC from a genetic basis
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
FDA grants priority review to expanded indication of flibanserin in HSDD
FDA clears image-guided navigation platform for focal therapy in prostate cancer
Category III CPT code issued for Enhanced Lithotripsy System
When to report 50320 with 49187 for nephrectomy procedures